Cell Therapy News/Articles, page-16703

This $6.5 billion move from Biogen is another example of why (sadly) I don’t believe Mesoblast will be around in 12 months time if we receive FDA approval for Remestemcel-L …. this drug treats a disease that only affects 1 in 50,000 people (or circa 6,000 people) in the USA - I also couldn’t see where it has data for multiple other indications like Remestemcel-L does ?


Remember, it’s all about money with big pharma and one of the global giants wanting something that the others don’t have that will contribute to and protect their future revenues … add to that Mesoblast’s MSC patent portfolio second to none along with many years of data and multiple treatments that have completed phase 3 trials so it might tempt more than one suitor, especially CLBP and CHF


https://www.cnbc.com/2023/07/28/bio...llion-to-bulk-up-rare-disease-portfolio-.html

Biogen to buy Reata for $6.5 billion to bulk up rare disease portfolio


Biogen agreed to buy biotech firm Reata Pharmaceuticalsfor nearly $6.5 billion to bolster its position in the rare disease drugs market while its older multiple sclerosis drugs face intense competition.

Through the deal, Biogen said it will gain Plano, Texas-based Reata’s recently approved drug Skyclarys to treat a rare genetic disorder that causes progressive damage to the nervous system.

Reata’s Skyclarys is the only approved treatment for Friedreich’s ataxia, which affects about one in every 50,000 people, in the United States.